ASGR1 hFc Chimera, Human
ASGR1 HFc Chimera, Human

The purity of ASGR1 hFc Chimera, Human is greater than 90% as determined by SEC-HPLC.

ASGR1 HFc Chimera, Human

ASGR1 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ASGR1 hFc Chimera, Human

ASGR1 is a liver-specific surface marker that is exclusively expressed in liver and mediates internalization and lysosomal degradation of blood asialoglycoproteins.
Z05043
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
hFc ASGR1 (Gln62-Leu291)
Accession # P07306-1
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 51.92 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 55-70 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS, 200mM L-Arginine (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • ASGR1 HFc Chimera, Human
    • ASGR1 HFc Chimera, Human

    The purity of ASGR1 hFc Chimera, Human is greater than 90% as determined by SEC-HPLC.

  • ASGR1 HFc Chimera, Human
    • ASGR1 HFc Chimera, Human

    ASGR1 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background ASGR1 is a liver-specific surface marker that is exclusively expressed in liver and mediates internalization and lysosomal degradation of blood asialoglycoproteins.
Synonyms ASGP-R 1; ASGPR 1; Hepatic lectin 1; HL-1; mHL-1; Asgr1; Asgr-1;

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.